Abstracts tagged "meta-analysis"

Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting
Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Ana Urruticoechea-Arana¹, Tatiana Cobo-Ibáñez², Virginia Villaverde García³, Montserrat Santos-Gómez⁴, Kelly Vargas Osorio⁵, Federico Díaz-González⁶, Leslie Fariñas Padrón⁵, Vanesa Calvo-Río⁷ and Ricardo Blanco Alonso⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, ⁶Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose:
Abstract Number: 610 • 2016 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Comparative Efficacy of Biologics in Treating Patients with Rheumatoid Arthritis: Assessment of Long-Term Radiographic Progression from Published Clinical Trials
Erin Murray¹, Yekaterina Butylkova¹, Alexandra Ellis¹, Martha Skup², Jasmina Kalabic³ and Vishvas Garg⁴, ¹Doctor Evidence, Santa Monica, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie Inc, North Chicago, IL
Background/Purpose: Previously, several studies have meta-analyzed clinical, functional or structural efficacy of biologics in treating rheumatoid arthritis (RA) patients. However, the comparative efficacy of biologics…
Abstract Number: 617 • 2016 ACR/ARHP Annual Meeting
Therapy in Patients with Rheumatoid Arthritis (RA) with Inadequate Response to Tumor Necrosis Factor Alpha Inhibitors (TNFi): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs
Maria A. Lopez-Olivo¹, Aliza Matusevich^2,3 and Maria Suarez-Almazor⁴, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ²General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The University of Texas, School of Public Health, Houston, TX, ⁴Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Up to one-third of the patients who receive TNFi lose responsiveness over time. Options available to these patients include treatment with an alternative TNFi…
Abstract Number: 1155 • 2016 ACR/ARHP Annual Meeting
The Effect of Nurse-Led Follow-up in Rheumatoid Arthritis. a Systematic Review and Meta-Analysis of Randomized Controlled Trails
Annette de Thurah^1,2, Bente Appel Esbensen^3,4, Ida K Roelsgaard⁴, Tove F Frandsen⁵ and Jette Primdahl^6,7, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ²Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ³Copenhagen Center for Arthritis Research (Copecare), Rigshospitalet, Copenhagen, DK, Copenhagen, Denmark, ⁴Department of Clinical Medicine, University of Copenhagen, Copenhagen, DK, Copenhagen, Denmark, ⁵The knowledge Center of Odense University Hospital, Odense University Hospital, Odense, DK, Odense, Denmark, ⁶King Christian X’s Hospital for Rheumatic Diseases, Graasten, Hospital of Southern Jutland, DK, Graasten, Denmark, ⁷Institute for Regional health Research, University of Southern Denmark, Odense, DK, Odence, Denmark
Background/Purpose: Due to a longer life expectancy in general, the treatment burden of RA is growing, and although treatment is generally becoming more effective and…
Abstract Number: 1206 • 2016 ACR/ARHP Annual Meeting
A Replication Study and Meta-Analysis Demonstrate the Influence of the mtDNA Haplogroups in the Rate of Incident Knee Osteoarthritis. Functional Explanation of This Association Using Transmitochondrial Cybrids
Ignacio Rego-Pérez¹, Mercedes Fernandez Moreno¹, Angel Soto-Hermida¹, Maria Eugenia Vazquez Mosquera¹, Estefanía Cortés-Pereira¹, Sara Relaño-Fernandez², Tamara Hermida-Gómez³, Sonia Pertega⁴, Rafael Garesse⁵, Natividad Oreiro³, Carlos Fernandez-Lopez¹ and Francisco J. Blanco^1,6, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo HospitalarioUniversitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ²Plataforma de Genómica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ⁴Unidad de Epidemiología Clínica y Bioestadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain, ⁵Departamento de Bioquímica, Instituto de Investigaciones Biomédicas "Alberto Sols" UAM-CSIC y Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Universidad Autónoma de Madrid 28029, Madrid, Spain, Madrid, Spain, ⁶Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain
Background/Purpose: The study of the mitochondria in the context of osteoarthritis (OA) attracted much attention. In this study we aimed to evaluate the influence of…
Abstract Number: 1212 • 2016 ACR/ARHP Annual Meeting
A Combined Large Scale Meta-Analysis Identifies COG6 As a Novel Shared Risk Locus for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Ana Márquez¹, Laura Vidal-Bralo², Luis Rodriguez-Rodriguez³, Miguel Angel González-Gay⁴, Alejandro Balsa⁵, Isidoro Gonzalez-Alvaro⁶, Patricia Carreira⁷, Norberto Ortego Centeno⁸, Maria del Mar Ayala Gutierrez⁹, Francisco José García-Hernández¹⁰, Francisca González Escribano¹¹, José Mario Sabio¹², Carles Tolosa¹³, Ana Suárez¹⁴, Antonio Gonzalez¹⁵, Leonid Padyukov¹⁶, Jane Worthington¹⁷, Timothy J. Vyse^18,19, Marta E. Alarcon Riquelme^20,21 and Javier Martín¹, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ²Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ³Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, ⁵Department of Rheumatology and Institute for Health Research (IdiPAZ), University Hospital La Paz, Madrid, Spain, ⁶Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁷Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ⁹Department of Internal Medicine, Hospital Carlos Haya, Málaga, Spain, ¹⁰Department of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹¹Department of Immunology, Hospital Universitario Virgen del Rocío (IBiS, CSIC, US), Sevilla, Spain, ¹²Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain, ¹³Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain, ¹⁴Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain, ¹⁵Laboratorio de Investigación 10 and Rheumatology Unit, Instituto de Investigación Sanitaria - Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁶Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ¹⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁸Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ¹⁹Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom, ²⁰Centro de Genómica e Investigación Oncológica (GENYO), Pfizer-Universidad de Granada-Junta de Andalucía, Granada, Spain, ²¹Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: One of the main limitations of the association studies in autoimmunity is the difficulty in identifying genetic risk variants with modest effects, given the…
Abstract Number: 367 • 2015 ACR/ARHP Annual Meeting
Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Xerxes Pundole¹, Maria A. Lopez-Olivo², Hira Cheema³, Gabriela Sanchez Petitto⁴, Maria E. Suarez-Almazor⁵ and Huifang Lu⁶, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Texas Tech Odessa, Odessa, TX, ⁴The University of Texas, Health Science Center, Houston, TX, ⁵The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶General Internal Medicine, AT &EC, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: The main goal of our study was to evaluate the efficacy and safety of bisphosphonates and/or general preventive strategies in the prevention and treatment…
Abstract Number: 439 • 2015 ACR/ARHP Annual Meeting
Progression of Radiographic Joint Destruction in Patients with Rheumatoid Arthritis Treated with a Biologic Agent in Combination with Methotrexate Versus a Biologic Alone: A Systematic Review and Meta-Analysis of Randomized Trials
Tanja Schjødt Jørgensen¹, Simon Tarp¹, Daniel E. Furst², Anna Døssing¹, Peter C. Taylor³, Henning Bliddal¹ and Robin Christensen¹, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose : One of the frequently claimed advantages of biologic agents is their potential to arrest radiographic progression. The ability of disease-modifying antirheumatic drugs (DMARDs;…
Abstract Number: 835 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis to Determine If the Prevalence of Scleroderma Renal Crisis Decreasing with Time
Matthew Turk¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease with increased mortality from various internal organ involvement. Scleroderma renal crisis (SRC) usually occurs…
Abstract Number: 1041 • 2015 ACR/ARHP Annual Meeting
Methotrexate Monotherapy and Methotrexate Combination Therapy with Traditional and Biologic Dmards for Rheumatoid Arthritis: A Cochrane Systematic Review and Network Meta-Analysis
Glen S. Hazlewood^1,2, Cheryl Barnabe³, George A. Tomlinson⁴, Deborah Marshall⁵, Daniel Devoe⁵ and Claire Bombardier⁶, ¹Institute of Health, Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶18 Strathearn Blvd, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare methotrexate based disease-modifying anti-rheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naïve to or after an inadequate response (IR) to methotrexate. …
Abstract Number: 1389 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis of the Prevalence of the Ocular Manifestations in All Inflammatory Rheumatic Diseases
Jacqueline Hayworth¹ and Janet E. Pope², ¹Medicine, University of Western Ontario and U of Toronto, Toronto, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Many inflammatory rheumatic diseases (IRD) are associated with ocular involvement. The prevalence of these complications is not fully known. This meta-analysis was performed to…
Abstract Number: 1781 • 2015 ACR/ARHP Annual Meeting
Comparative Efficacy and Safety of Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide As Induction Therapy for Lupus Nephritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee and Gwan Gyu Song, Rheumatology, Korea University Medical Center, Seoul, South Korea
Background/Purpose: Cyclophosphamide (CYC) regimens improved renal outcomes, and have long been considered the gold standard for inducing renal remission and preventing renal flares in proliferative…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 2475 • 2015 ACR/ARHP Annual Meeting
Association Between Fibromyalgia and Suicidal Risk: A Systematic Review and Meta-Analysis
Sikarin Upala¹ and Anawin Sanguankeo², ¹Internal Medicine, Bassett Medical Center, Cooperstown, NY, ²Bassett Medical Center, Cooperstown, NY
Background/Purpose: Chronic pain conditions are related poor overall health, economic burden, and mental disorders including suicidal ideation (SI), suicide attempts (SA), and completed suicides. Fibromyalgia…
Abstract Number: 2858 • 2015 ACR/ARHP Annual Meeting
A Phosphodiesterase 4 Inhibitor for Psoriatic Arthritis: Systematic Review and Meta-Analysis
Ignacio-Alfredo Valerio-Morales¹, Maria A. Lopez-Olivo², Xin Pan³ and Maria E. Suarez-Almazor⁴, ¹Rheumatology, National Institute of Rehablitation, Mexico, Mexico, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Inhibition of phosphodiesterase (PDE) family enzymes is now recognized as target to develop new psoriatic arthritis (PsA) drugs. We conducted a systematic review to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].